Modifications in P62 occur due to proteasome inhibition in alcoholic liver disease

被引：42

作者：

Bardag-Gorce, F ^{[1
]}

Francis, T ^{[1
]}

Nan, L ^{[1
]}

Li, J ^{[1
]}

Lue, YH ^{[1
]}

French, BA ^{[1
]}

French, SW ^{[1
]}

机构：

[1] Harbor UCLA Med Ctr, Torrance, CA 90502 USA

来源：

LIFE SCIENCES | 2005年 / 77卷 / 20期

关键词：

alcoholic liver disease; P62; proteasome inhibition;

D O I：

10.1016/j.lfs.2005.04.020

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

P62 is capable of binding the polyubiquitin chain that targets proteins for degradation by the proteasome through its ubiquitin associated domain (UBA). Immunostaining of hepatocytes from human liver with alcoholic hepatitis showed colocalization of ubiquitin and P62 in Mallory bodies. Rats fed ethanol chronically and their controls showed that P62 is colocalized with the proteasome in hepatocytes as shown by confocal microscopy. P62 cosedimented with 26S proteasomes isolated from livers of control and alcohol fed rats. P62 was increased in the 26S proteasome fraction when the proteasome chymotrypsin-like (ChT-L) activity decreased in rats fed ethanol. PS-341, a potent proteasome inhibitor was used to compare the inhibition of the proteasome with the inhibition which occurs with ethanol feeding. P62 protein levels were also increased in the purified proteasome fraction of rats given PS-341. This data indicates that modifications in P62 occur due to proteasome inhibition in experimental alcoholic liver disease. (c) 2005 Elsevier Inc. All rights reserved.

引用

页码：2594 / 2602

页数：9

共 21 条

[1] The proteasome inhibitor, PS-341, causes cytokeratin aggresome formation [J].